Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

NCT01352663 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business strategy decision

Conditions

Type I Diabetes

Interventions

BIOLOGICAL: Wockhardt's Insulin Analogue (Recomb)
BIOLOGICAL: Lantus®

Sponsor

Wockhardt